The European signal: regulators are rewriting how cancer drugs are given
The most concrete European news in this set is about schedules and combinations rather than new molecules. The EU's medicines committee (CHMP) adopted a positive opinion on an alternative Libtayo dosing schedule across all approved indications: 700 mg as a 30-minute IV infusion every six weeks, after an initial 12 weeks of 350 mg every three weeks.1 For patients that means fewer hospital visits. For health systems it means fewer infusion slots used.1
In July, the same committee recommended Gilead's Trodelvy plus Keytruda for PD-(L)1-positive first-line metastatic triple-negative breast cancer.2 Gilead said a second first-line approval would establish Trodelvy as a backbone therapy across PD-L1 status in the European Union.2 Evandro de Azambuja said: "People with metastatic triple-negative breast cancer need effective treatment options as early as possible in the course of their disease, particularly when their tumors express PD-L1."2
Two other European data points show how new products reach the market. Novocure received a CE Mark for Optune Pax in locally advanced pancreatic cancer, and Germany is the first EU market to launch.3 Novocure reported quarterly net revenues of $184 million, up 16% year-over-year, with more than 280 active patients on Optune Pax as of June 30, 2026.3 Separately, Kyowa Kirin International reported the final MINT study of mogamulizumab: 109 patients across 18 German centres, with median time-to-next-treatment of 14.9 months, a 62.4% best overall response rate and 20.2-month median progression-free survival.4 This is real-world data from routine care rather than a controlled trial.4
The US calendar that European investors will still watch
The FDA approved Tecentriq and Tecentriq Hybreza with a fluoropyrimidine and oxaliplatin for adjuvant stage III dMMR colon cancer, based on the Phase III ATOMIC study. It is the twelfth U.S. indication for Tecentriq.5 Summit's Biologics License Application for ivonescimab, based on HARMONi trial results, has a PDUFA goal date of November 14, 2026.6 Moderna and Merck plan to present detailed intismeran results at ESMO on Oct. 24 and to engage regulators on potential filings.7 Those are plans and goal dates, not outcomes. None of the three is a European decision.
Talent is also moving. Everest Medicines hired two former Moderna oncology translational scientists, Brandon Coder and Lakshmi Srinivasan, into senior translational roles.8 The dossier does not say why, so we draw no conclusion beyond the hires.
What a late-stage bet costs: Summit's checked filings
Summit is the one company in this set whose numbers have been checked against SEC filings. It reported zero revenue in both FY2023 and FY2024.9 Its net loss was $614.9 million in FY2023, $221.3 million in FY2024 and $1,079.6 million in FY2025.9 The FY2025 loss is roughly five times the FY2024 figure. Loss per share moved from -$0.99 to -$0.31 to -$1.44 over the same years.9
Cash spending tells a steadier story. Operating cash outflow was $76.8 million in FY2023, $142.1 million in FY2024 and $322.9 million in FY2025.9 Capital expenditure rose from $128,000 to $139,000 to $657,000.9 Year-end cash was $71.4 million, $104.9 million and $225.3 million.9 Note that FY2025 year-end cash was lower than that year's operating cash burn, so the company's position depended on raising more money.
Quarterly cash balances swing sharply: $106.5 million in Q1 2026, then $419.4 million in Q2 2026.9 The filings give the balances but not the reason for the jump. We will not guess at its source. Readers should also see the gap between FY2023's net loss ($614.9 million) and its operating cash outflow ($76.8 million).9 The dossier does not explain that gap, so it should not be read as spending alone. The figure to watch is cash against burn, with a regulatory decision due on November 14.6
The dossier does not say how much of Summit's collaboration with AstraZeneca and Daiichi Sankyo on ivonescimab plus Datroway in first-line TNBC is funded by whom, so we cannot say who bears these costs. Likewise, we have no price or terms for the McKesson and CD&R acquisition of Option Care Health, whose headquarters are in Bannockburn, IL.
The AI claim: an executive's vision, not a result
AstraZeneca, a FTSE 100 company, supplies the AI storyline. AstraZeneca's Puja Sapra describes a "lab of the future": "Where a self-driving car uses sensors and models to navigate its environment, this system uses AI to make predictions, robotic systems to execute experiments, and instruments to generate data."10 She also states: "Data is our differentiator."10
Sapra is candid about the limits. "One of the hardest problems in de novo design is predicting whether a computationally generated molecule will be safe in the human body."10 She says virtual clinical trials could generate biological signals "without traditional testing bottlenecks" and are "a critical missing piece in closing the loop between AI-generated designs and clinical-ready candidates."10 The wording is revealing: the piece is about potential, and her own text calls this a missing piece. She also stresses oversight: "With more autonomous systems, human oversight remains at the heart of this approach—ensuring explainable and ethical AI for the benefit of patients."10 That is a point European regulators will likely care about, though the dossier contains no EU regulatory statement on it.
Via News's analysis is that these AI statements are opinion and forecast. The dossier holds no demonstrated drug, trial or timeline produced by the approach. On reliability: the MIT Technology Review piece carries a measured reliability of 0% of 11 checked claims held up, a small sample but a poor record.10 The wire releases (NewsEOD) score 56% of 4,960 checked claims.2,3,4 Neither score is high. Company announcements in particular present their own results favourably. Treat the regulatory and financial facts above, which come from agencies and filings, as firmer ground than the AI narrative.
What to watch
- Oct. 24: whether the intismeran ESMO data match what Moderna and Merck have said and whether regulatory filings follow.7
- Nov. 14: the FDA's decision on ivonescimab, and Summit's cash against its burn.6,9
- Europe: whether the European Commission follows the CHMP on Libtayo and Trodelvy plus Keytruda, which the dossier does not yet record.1,2
- AI: a named molecule or trial result from AstraZeneca's approach, which would turn forecast into evidence.10
